Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ABL2 | P42684 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096348 | 1.00 | ADH1A (0.32) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL29966567 | 1.00 | ADH1A (0.32) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL9885494 | 0.82 | ADH1A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL29375160 | 0.82 | ADH1A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL584232 | 0.82 | ADH1A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL13293994 | 0.82 | ADH1A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL16847796 | 0.81 | ADH1A (0.30) | ADH1AKITFLT1FLT4KDR | |
| Hydrochloric Acid SCHEMBL16933151 | 0.81 | ADH1A (0.44) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL16942004 | 0.77 | CTSB (0.41) | KDM4EHTTHPRT1PKM | |
| SCHEMBL3563974 | 0.77 | CTSB (0.41) | KDM4EHTTHPRT1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250297011-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12281165-B2 | Anti-B7-H4 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3693391-B1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11860156-B2 | Bioanalytical analysis of site-specific antibody drug conjugates | GENENTECH, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230130874-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-109313200-B | Bioanalytical methods for characterizing site-specific antibody-drug conjugates | 豪夫迈·罗氏有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016040724-A1 | ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040868-A1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040856-A2 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040723-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160075787-A1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2016020369-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2016-02-11 | — | — | WO | disclosed |
| WO-2015095212-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015023355-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2008039087-A2 | INDOLINE DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20230130874-A1 | Cysteine Engineered Antibodies and Conjugates | GCLC, CTH, CBS | ADH1A 3345/4885KIT 3824/4885FLT1 2438/4885 |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GUSB, DNPEP, FUCA2 | ADH1A 1144/4885KIT 3494/4885FLT1 986/4885 |
| US-11860156-B2 | Bioanalytical analysis of site-specific antibody drug conjugates | GUSB, DNPEP, FUCA2 | ADH1A 1351/4885KIT 3599/4885FLT1 933/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20250297011-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | CD44, NECTIN4, H1-4 | ADH1A 3406/4885KIT 1608/4885FLT1 3592/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | IGLV6-57, GCLC, QPCTL | ADH1A 4021/4885KIT 4135/4885FLT1 2107/4885 |
| US-12281165-B2 | Anti-B7-H4 antibodies and immunoconjugates | CD44, NECTIN4, H1-4 | ADH1A 3406/4885KIT 1608/4885FLT1 3592/4885 |
| US-20160075787-A1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | BCL9, MCL1, IGSF11 | ADH1A 2126/4885KIT 3498/4885FLT1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.